CTLA4 and neoplasm: Screening for onco-proteomic sEV-based biomarkers in HNSCC provided the first evidence that immunoregulatory proteins such as PD-1, PD-L1, and CTLA-4 can be utilized as markers of tumor progression and might play an important functional role due to their immunosuppressive effects [40].